Oy Medix Biochemica Ab
Headquarters
Klovinpellontie 3
FI-02180 Espoo
Finland
Email: sales@medixbiochemica.com

Medix Biochemica USA Inc.
10850 Metro Court
Maryland Heights, MO 63043
United States of America
Email: sales@medixbiochemica.com

Product Datasheet

Anti-h PSA 8312 SPRN-5
100139

Oy Medix Biochemica Ab
Headquarters
Klovinpellontie 3
FI-02180 Espoo
Finland
Email: sales@medixbiochemica.com

Medix Biochemica USA Inc.
10850 Metro Court
Maryland Heights, MO 63043
United States of America
Email: sales@medixbiochemica.com

Product Name	Anti-h PSA 8312 SPRN-5
Catalog Number	100139
Description	Monoclonal mouse antibody, cultured in vitro under conditions free from animal-derived components.
Species/Host	Mouse
Tested Applications	FIA
Alternative Names	Prostate-specific Antigen, Kallikrein-3 (KLK3), P-30 antigen, gamma-seminoprotein
Brand	Medix Biochemica
Form/Appear	Liquid, may turn slightly opaque during storage
Concentration	5.0 mg/ml (+/- 10 %)
Storage	+2–8 °C
Note	Clone 8312 reacts with non-reduced and reduced intact PSA as well as with reduced PSA fragments (Rye et al., 1999). In the same study affinities for free-PSA and PSA-ACT-complex were, 7.5 x 10-9 mol/l and 1.03 x 10-10, respectively. They also noted that antibodies binding to epitope group 6 form a good pair with antibodies from groups 1 and 3. Clone 8312 crossreacts with human kallikrein-2 (Rye, 1999a). Clone 8312 was coded as 5E4 in Rye et al. (1999).
Isotype	IgG1
Clonality	Monoclonal
Epitope	Residues 3–11, group 6a as described in Rye et al. (1999)
Purity	≥ 95 %
Affinity constant	KA= 3 x 10^9 1/M
Buffer	37 mM citrate, 125 mM phosphate, pH 6.0, 0.9 % NaCl, 0.095 % NaN3 as a preservative
IEF Profile	6.3–7.0
Cross Reactivity	PSA/a1-ACT complex 15 %. Does not recognize human kallikrein-2 or PAP.
Specificity	Antibody recognizes human prostate-specific antigen
Shelf Life	36 months
References	Rye, P.D., Bormer, O.P. and Paus, E. (guest editors) (1999), ISOBM TD-3 International Workshop on monoclonal antibodies against prostate-specific antigen. Tumor Biol., 2(suppl 1):1-94